Skip to content

Successful treatment for serious depression with suicidal risk in a heart transplant patient.

María Del Mar Arango-Posada, Ana Isabel Prada-Escobar, Carolina Marín-Hernández, Veronica Monsalve-Franco, Diana Restrepo-Bernal

Revista Colombiana de psiquiatria 2024 DOI: 10.1016/j.rcpeng.2022.03.001 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population 55-year-old man with a heart transplant
Interventions Mirtazapine Ketamine infusion
Dose 30 mg/night mirtazapine, 24 h ketamine infusion
Duration One week of mirtazapine, 24-hour ketamine infusion with 24-hour follow-up
Topics Depression Ketamine
Keywords Heart transplantation Ketamina Riesgo suicida Suicide risk Trasplante de corazón Trastorno depresivo Depression therapy Heart surgery Ketamine treatment Suicide prevention Transplant psychiatry
Key findings Ketamine infusion rapidly resolved suicidal ideation and improved mood in a heart transplant patient with major depression.

Abstract

Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes. We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 h, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 h after the infusion. Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis. Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.

Comparable studies

Other case reports and case series on ketamine for depression, most cited first.

Study Year Design Participants
Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. A patient with treatment-resistant depression and comorbid generalized anxiety... 2025 Case report n = 1
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression Patients with enduring eating disorders and treatment-resistant depression 2021 Case series n = 4
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series Veterans with co-morbid depression and PTSD 2022 Retrospective case series n = 35
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa Patients with anorexia nervosa and a comorbid depressive disorder treated at a private... 2023 Case report n = 4
Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder Patients with treatment-resistant depression and comorbid PTSD 2023 Case series n = 5

Explore topics

By condition and practice